Skip to main content
PepStack

CJC-1295

GH Secretagogue
CJC1295CJC-1295 without DACCJC-1295 with DACDAC:GRF

Overview

CJC-1295 is a synthetic peptide initially developed to act as a growth hormone secretagogue. It is an analog of growth hormone-releasing hormone (GHRH) and is designed to stimulate the pituitary gland to release more growth hormone. The compound is available in two forms: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC, which differ in their pharmacokinetic properties. The synthesis of CJC-1295 involves peptide bond formation through solid-phase peptide synthesis, a common method for producing peptides. Researchers have primarily investigated CJC-1295 for its potential to increase growth hormone levels and its subsequent effects on muscle growth, fat loss, and recovery. Studies have shown that CJC-1295 can significantly elevate serum growth hormone and IGF-1 levels, which are associated with anabolic effects. Other areas of research include its potential impact on aging and metabolic disorders. The mechanism of action of CJC-1295 involves binding to the growth hormone-releasing hormone receptor (GHRHR) on pituitary cells, stimulating the release of growth hormone. This process is mediated through the activation of the cAMP pathway, which leads to increased synthesis and secretion of growth hormone. CJC-1295 with DAC has an extended half-life due to the presence of the Drug Affinity Complex, which allows for sustained release and prolonged action. The pharmacokinetic properties of CJC-1295 vary between its forms. CJC-1295 with DAC has a half-life ranging from 6 to 8 days, allowing for less frequent dosing, while CJC-1295 without DAC has a shorter half-life of approximately 30 minutes. The compound is stable when lyophilized and should be stored at low temperatures to maintain its integrity. Currently, CJC-1295 is not approved for therapeutic use by major regulatory agencies. It is primarily available as a research chemical, and its use is restricted to scientific studies. Researchers continue to explore its potential applications, but its regulatory status remains limited.

Mechanism of Action

CJC-1295 acts by binding to the growth hormone-releasing hormone receptor (GHRHR) on the pituitary gland, activating the cAMP pathway. This activation leads to increased synthesis and secretion of growth hormone, which in turn stimulates the production of insulin-like growth factor 1 (IGF-1).

Molecular Data

FormulaC165H269N47O46
Molecular Weight3647.2 g/mol
CAS Number446262-90-4
PubChem CID91971820

Half-Life

Subcutaneous~6 to 8 days (with DAC)
IntranasalNot applicable
OralPoor bioavailability

The presence of DAC in CJC-1295 extends its half-life significantly compared to the form without DAC.

Storage

Lyophilized

Stable for 2+ years at -20°C, 12 months at 4°C

Reconstituted

Use within 14 days when refrigerated at 4°C

Avoid

Avoid repeated freeze-thaw cycles, direct light

Solvent

Bacteriostatic water or sterile saline recommended

Solubility

CJC-1295 is soluble in water and aqueous solutions but has limited solubility in organic solvents like acetonitrile and DMSO.

Legal Status

🇩🇪DE

Not approved as a medicinal product. Not a controlled substance. Sale as research chemical is a legal grey area.

🇺🇸US

Not approved by the FDA for therapeutic use. Not scheduled by the DEA.

🇦🇺AU

Not listed in the TGA's approved medicines. Considered a research chemical.

🇬🇧UK

Not approved by the MHRA for medical use. Available only for research purposes.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

7 Research Publications

A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.

Unknown

Drug testing and analysis · 2019

Researchers studied CJC-1295, a peptide that boosts growth hormone production, and developed a method to confirm its presence in horse blood samples. They found that their new detection technique could identify CJC-1295 at very low concentrations, which is important for monitoring potential abuse in equine athletes.

  • Researchers found that CJC-1295 can stimulate growth hormone production for over six days after a single dose.
  • The study demonstrated a new method using LC-MS/MS to confirm the presence of CJC-1295 in equine plasma.
  • CJC-1295 was detectable at concentrations as low as 180 pg/mL in 1 mL of equine plasma.
PubMed

An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.

Unknown

Drug testing and analysis · 2019

Researchers studied CJC-1295, a peptide that boosts growth hormone release, and developed a new test to detect it in horse blood. They found that this test can identify CJC-1295 even when it is bound to proteins, which makes it harder to detect using standard methods. This advancement could help monitor the use of this performance-enhancing substance in racehorses.

  • Researchers developed an immuno-polymerase chain reaction assay that can detect CJC-1295 at very low concentrations in equine plasma.
  • The assay can identify CJC-1295 even when it is conjugated to plasma proteins, which complicates detection with traditional methods.
  • The effectiveness of the test was confirmed in thoroughbred racehorses after they received CJC-1295.
PubMed

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.

Review

Substance use & misuse · 2016

Researchers explored how women discuss the use of CJC-1295, a synthetic growth hormone, in online forums. They found that women are interested in this substance for benefits like weight loss, muscle enhancement, and improved skin, but also express concerns about potential health risks and dosage issues specific to females.

  • Researchers observed that women use CJC-1295 primarily for weight loss, muscle enhancement, and skin improvement.
  • The study found that forum users were knowledgeable about various performance-enhancing drugs and their effects.
  • Concerns were raised about the unique health risks women may face when using synthetic growth hormones like CJC-1295.
PubMed

Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.

Human

Drug testing and analysis · 2010

Researchers found that an unknown pharmaceutical preparation analyzed by Norwegian authorities contained a peptide called CJC-1295, which stimulates growth hormone release. This substance is prohibited in sports due to its potential performance-enhancing effects and is reportedly available in the bodybuilding community.

  • The analysis revealed the presence of a 29 amino acid peptide consistent with CJC-1295.
  • CJC-1295 is classified as a prohibited substance by the World Anti-Doping Agency (WADA).
  • There are concerns about the illicit use of this peptide in bodybuilding and athletic circles.
PubMed

Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.

Unknown

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2009

Researchers studied the effects of CJC-1295, a growth hormone-releasing hormone analog, on serum proteins in healthy young men. They found changes in specific proteins after treatment, suggesting these proteins could serve as new biomarkers for growth hormone and insulin-like growth factor 1 activity.

  • Two proteins decreased in intensity after CJC-1295 treatment, indicating potential markers of growth hormone activity.
  • Three proteins increased after treatment, including beta-hemoglobin and albumin fragments, which may relate to insulin-like growth factor 1 levels.
  • The study highlights the need for further research to understand how these proteins connect to growth hormone and insulin-like growth factor 1 functions.
PubMed

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.

Animal

American journal of physiology. Endocrinology and metabolism · 2006

Researchers studied the effects of CJC-1295, a long-lasting growth hormone-releasing hormone analog, on mice lacking the GHRH gene. They found that daily administration of CJC-1295 normalized growth and body composition in these mice, suggesting its potential for improving growth in similar conditions.

  • CJC-1295 administration led to normal body weight and length in mice lacking the GHRH gene.
  • Mice treated every 48 and 72 hours showed better growth compared to those receiving a placebo.
  • The treatment increased growth hormone production in the pituitary gland, indicating cell proliferation.
PubMed

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

Human

The Journal of clinical endocrinology and metabolism · 2006

Researchers studied CJC-1295, a long-acting hormone that stimulates growth hormone (GH) release, in healthy adults. They found that CJC-1295 significantly increased GH and insulin-like growth factor I (IGF-I) levels for several days after administration, and it was safe and well tolerated.

  • CJC-1295 led to a 2- to 10-fold increase in GH levels for over 6 days.
  • IGF-I levels increased by 1.5- to 3-fold and remained elevated for up to 28 days after multiple doses.
  • The study reported no serious adverse reactions, indicating that CJC-1295 was safe for use in the participants.
PubMed

Track CJC-1295 in PepStack

Log your research cycles, set reminders and visualize serum levels.

Download on theApp StoreGet it onGoogle Play

This page is for informational and research purposes only. All information is based on published scientific literature. Nothing on this page constitutes medical advice or replaces consultation with a qualified healthcare professional.